Chinese creatures or Nasdaq retreat

According to I U.S. News, June 24, Nasdaq-listed company China Biology (CHBT).　　Nasdaq) confirmed that, as the company has not yet submitted its annual financial report for the year ended March 31, 2011, the exchange filed that the company is no longer complying with the rules on Nasdaq listing, and that the Nasdaq has submitted a notification of delisting to Chinese creatures for the protection of investors. The previous two days, the independent audit of Chinese biology, Hong Kong lixin German accounting firm Limited (BDO 2¥q, hereinafter referred to as "BDO") and the chief Financial officer Travis Cai successively resigned on June 22 and June 23.　　BDO said in his letter of resignation that Chinese organisms could have a significant impact on the financial statements and that BDO could not gather evidence to assess whether the company had tampered with the financial statements and other violations that would have a significant impact on the financial statements.　　Yesterday evening, this reporter repeatedly call China Biological CEO Song Jin-an and chief Administrative Officer 闫屹泓 Mobile phone, are no answer to listen. In August 2010, the number of Chinese bio-Biotech subsidiaries in China and the SEC (US Securities Regulatory Commission) reported a mismatch, first questioned by Citron Research, a US researcher, that the company's share price has climbed from $14 to around $10 in the next one months.　　The company then invited U.S. investors to visit the site on investor day, and the share price soared to $18. Since then, because of Citron's continued follow-up to the query, China's biological stock price volatility, volume volume.　　By the end of March, a Web page named Bdowatch, including the discrepancy between the Chinese bio-SEC document and the documents of the SAIC (China State Administration for Industry and Commerce), and the existence of an undisclosed lawsuit, was informed that the Web page was based on a survey by Citron Research and its partner's fund managers. Since then, Chinese bio-stock prices have been slow to callback, a US fund manager once told reporters he was puzzled that "we don't understand why suddenly someone is interested in this dubious company, and I think there must be insider trading," he said in the past one months, when a number of celebrities have repeatedly launched a deal to buy shares at high prices. But we don't know what it is.　　"At that time, the fund manager was writing a survey on Chinese biology. Until June 15, China's biological requirements to postpone the submission of the annual financial report as at March 31, 2011, and the U.S. Eastern time on the same day 15:35 by Nasdaq suspension. In accordance with the requirements of the Exchange notice, if the company wishes to continue listing transactions, it is necessary to supply relevant compliance information and reports before July 5, 2011 and to be evaluated by the exchange. (Lu Jinyuan)